The hs-CRP Normal Range, and Why the Single Number Misleads
High-sensitivity C-reactive protein (hs-CRP) is conventionally read against three bands: below 1.0 mg/L is low, 1.0 to 3.0 mg/L is intermediate, and above 3.0 mg/L is high. Values above roughly 10 mg/L are generally treated as an acute-phase response rather than a cardiovascular risk stratifier, and the usual advice is to retest after a few weeks. Note the units. Some labs report mg/dL, where the same cut points are 0.1, 0.3, and 1.0 mg/dL, and a tenfold unit error is the single most common misreading of this test.
Those bands come from cardiovascular epidemiology and not from a distribution of healthy people. They are risk tertiles, so “normal” is a misnomer. A 2.4 mg/L result is a population-average value that sits in the middle risk band. It is not an abnormal lab value. The more useful question for someone with their own data is where their personal set point lies and how much it moves.
Where the cut points come from
CRP is a pentameric acute-phase protein made by hepatocytes, largely in response to interleukin-6 signaling. Ordinary CRP assays were built to detect infection and report down to about 5 to 10 mg/L. The high-sensitivity version uses immunoturbidimetric or immunonephelometric detection with latex-particle enhancement, reaching a functional sensitivity near 0.1 to 0.2 mg/L. That extra resolution is what made the low end interpretable.
The 1 and 3 mg/L thresholds were established in prospective cardiovascular cohorts, where hs-CRP added information about future events beyond lipids alone. Reviews of inflammatory biomarkers in coronary artery disease place hs-CRP as the best-validated of a large candidate set, with most alternatives failing to add independent predictive value in large cohorts.1 The same literature frames it as a risk modifier used alongside lipids and blood pressure rather than a standalone marker.2 Interpretation of your cardiovascular risk belongs with a clinician who can see the rest of your picture.
The upper boundary near 10 mg/L matters for a practical reason. Above it, the signal is usually dominated by something acute. A viral infection, a dental abscess, a recent hard training block or a healing injury can all push a person from 0.8 to 15 mg/L and back within two weeks. Reading that as a chronic risk value is a mistake.
A single draw is close to useless
The biological variability of hs-CRP is large. Within-person coefficients of variation commonly reported are in the range of 30 to 60 percent, far larger than the analytical CV of a good assay, which is typically under 5 percent at 1 mg/L. The measurement is precise. The thing being measured moves.
The practical consequence is that a lone result tells you little about your set point. If you measure once at 3.4 mg/L, the probability that your long-run average is below 3 is substantial. We would treat any single hs-CRP as a data point with a wide interval and no interpretation attached until there are at least three draws.
Our approach: measure three times, spaced two to four weeks apart, in the same pre-analytic conditions. Take the median, not the mean, because the distribution is right-skewed and a single infection ruins an average. Then repeat the triplet every six to twelve months. This gives you a personal baseline with a standard error you can reason about, which is what you need before any change in a follow-up value means anything.
What moves the number
Adiposity is the largest non-acute driver in most people. Adipose tissue secretes IL-6, and hs-CRP tracks visceral fat mass closely enough that it behaves partly as an adiposity marker. This is why hs-CRP correlates with the components of metabolic syndrome. A study of 7,284 subjects found hs-CRP levels substantially higher in those meeting metabolic syndrome criteria, and rising with the number of components present.3 In a cohort of healthy men, higher hs-CRP within the conventionally normal range predicted incident metabolic syndrome. An increase over time predicted it more strongly than a stable level.4
That last finding is the argument for longitudinal measurement in one sentence. The trajectory carried information the cross-sectional value did not.4
Glycemic status matters too. A comparison of newly diagnosed diabetes groups found hs-CRP differed depending on which diagnostic criterion identified them, with the highest values in those identified by two-hour post-load glucose.5 If you have continuous glucose data, pairing post-meal excursion patterns with a stable hs-CRP baseline is more informative than either alone.
Other confounds worth tracking in a log alongside each draw:
- Infection or vaccination in the prior three weeks. Both can raise hs-CRP severalfold.
- Strenuous exercise in the prior 48 to 72 hours, especially eccentric load or a long endurance effort.
- Sleep deprivation and acute psychological stress, which produce smaller but real increases.
- Oral estrogen, which raises hs-CRP through a first-pass hepatic effect. Transdermal routes generally do not.
- Periodontal disease, which is a common overlooked source of low-grade chronic elevation.
- Genetic variation at the CRP locus. Common variants shift baseline hs-CRP by meaningful amounts without changing the underlying inflammatory state. If you have whole-genome data, this is checkable.
Reading a low value
A low hs-CRP is reassuring for cardiovascular risk stratification. It does not rule out inflammatory disease. CRP production requires IL-6 drive and a functioning liver, and a subset of people with active inflammatory conditions maintain normal hs-CRP. In Crohn’s disease specifically, a meaningful fraction of patients have active disease with low hs-CRP. Alternative markers such as plateletcrit have been studied precisely because of that gap.6 If you have symptoms, a normal hs-CRP is not a negative test, and that assessment belongs to a clinician.
The other side is specificity. hs-CRP rises in many unrelated contexts. It has been studied as an adjunct marker in malaria, where levels track parasite density and morbidity.7 It rises in neonatal sepsis, though more slowly than IL-6.8 It has even been examined as a signal of cardiotoxicity during trastuzumab therapy in HER2-positive breast cancer.9 A number that moves for this many reasons cannot be interpreted without context.
How to handle the data
Keep hs-CRP as a time series. Do not leave it as a lab value in a PDF. A minimal schema that has served us well holds the following.
- date
- time of draw
- value in mg/L
- assay and lab identifier
- fasting status
- hours since last hard exercise
- a free-text note for infections or injuries
Store it as CSV or in a small SQLite table so you can join it against other panels.
Pin the lab and assay if you can. Different immunoturbidimetric platforms are standardized against the same reference preparation, but between-method differences of 10 to 20 percent at low concentrations are common. Switching labs mid-series introduces a step change you will misread as a biological trend. If you must switch, run one draw split across both to estimate the offset.
When you look for change, compare medians of triplets. Do not compare individual points. A shift from a median of 2.6 to 1.4 mg/L across two triplets is credible. A shift from 2.6 to 2.1 in single draws is noise. Plot the series on a log scale, since hs-CRP behaves roughly log-normally and a log plot makes proportional changes visually comparable.
Questions people also ask
What is the normal range for an hs-CRP test?
Below 1.0 mg/L is low, 1.0 to 3.0 mg/L is intermediate, and above 3.0 mg/L is high. Above about 10 mg/L usually reflects an acute process, and retesting after two to three weeks is standard practice. Convert carefully if your report uses mg/dL.
Is hs-CRP of 3.5 mg/L something to worry about?
On its own it is not interpretable. Repeat it twice more, several weeks apart. Do this away from infection and hard training, then look at the median. Persistent values above 3 mg/L warrant a conversation with a clinician, who will read them alongside lipids, blood pressure and body composition.
What is the difference between CRP and hs-CRP?
They measure the same protein with different lower limits of detection. Standard CRP reports reliably from roughly 5 to 10 mg/L upward and is used for infection and acute inflammation. hs-CRP resolves down to about 0.1 to 0.2 mg/L, which is what makes the 1 and 3 mg/L risk bands measurable.
Can hs-CRP be too low?
There is no established lower limit of concern. Very low values are common in lean, young, non-smoking people. The relevant caution is that a low value does not exclude active inflammatory disease.6
How often should I measure it?
We would do a triplet of draws at baseline, then a triplet every six to twelve months. Measuring more often without controlling exercise, infection and sleep produces a noisy series that is hard to read. The trajectory across years is where the information sits.4
Footnotes
-
Epaminondas Zakynthinos, Nikolitsa Pappa. Inflammatory biomarkers in coronary artery disease. Journal of Cardiology, 2009. https://doi.org/10.1016/j.jjcc.2008.12.007 ↩
-
Sotirios Tsimikas, James T. Willerson, Paul M. Ridker. C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. Journal of the American College of Cardiology, 2006. https://doi.org/10.1016/j.jacc.2005.10.066 ↩
-
S R Mirhafez, M Ebrahimi, M Saberi Karimian, et al. Serum high-sensitivity C-reactive protein as a biomarker in patients with metabolic syndrome: evidence-based study with 7284 subjects. European Journal of Clinical Nutrition, 2016. https://doi.org/10.1038/ejcn.2016.111 ↩
-
Kijung Yoon, Seungho Ryu, Jieun Lee, et al. Higher and increased concentration of hs-CRP within normal range can predict the incidence of metabolic syndrome in healthy men. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2018. https://doi.org/10.1016/j.dsx.2018.06.008 ↩ ↩2 ↩3
-
Yildiz Tutuncu, Ilhan Satman, Selda Celik, et al. A Comparison of hs-CRP Levels in New Diabetes Groups Diagnosed Based on FPG, 2-hPG, or HbA1c Criteria. Journal of Diabetes Research, 2016. https://doi.org/10.1155/2016/5827041 ↩
-
Jian Tang, Xiang Gao, Min Zhi, et al. Plateletcrit: A sensitive biomarker for evaluating disease activity in C rohn’s disease with low hs‐ CRP. Journal of Digestive Diseases, 2015. https://doi.org/10.1111/1751-2980.12225 ↩ ↩2
-
Otchere Addai-Mensah, Max Efui Annani-Akollor, Linda Ahenkorah Fondjo, et al. High-Sensitivity C-Reactive Protein: A Potential Ancillary Biomarker for Malaria Diagnosis and Morbidity. Disease Markers, 2019. https://doi.org/10.1155/2019/1408031 ↩
-
Purushothaman Ganesan. Evaluation of IL-6, CRP and hs-CRP as Early Markers of Neonatal Sepsis. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016. https://doi.org/10.7860/jcdr/2016/19214.7764 ↩
-
Adedayo A. Onitilo, Jessica M. Engel, Rachel V. Stankowski, et al. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Research and Treatment, 2012. https://doi.org/10.1007/s10549-012-2039-z ↩
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.